首页 > 最新文献

Experimental & Clinical Cardiology最新文献

英文 中文
Evidence-performance gap in primary care revisited in patients with diabetes 糖尿病患者初级保健的循证表现差距
Pub Date : 2014-01-01 DOI: 10.5167/UZH-95058
S. Djalali, F. Mikulicic, K. Woitzek, C. Chmiel, O. Senn, T. Rosemann, M. Vecellio
Evidence-performance-gaps between guidelines and treatment of type 2 diabetes (T2DM) in daily practice have been reported, especially in primary care. We aimed to assess the potential gap comparing current treatment in primary care with guidelines and patients’ characteristics from large clinical trials that guidelines are based on, namely UKPDS, ACCCORD, ADVANCE, STENO-2 and VADT. Methods: We undertook a cross-sectional study and extracted data on 541 patients with T2DM from a clinical information system of a GP network in Switzerland. Results: Our study population was comparable to patients in ACCORD, ADVANCE and VADT at baseline. Patients in UKPDS and STENO-2 differed in age and disease duration. HbA1c-levels (7.3%), LDL-level (2.6 mmol/l), systolic and diastolic (135/78 mmHg) blood pressure were lower in our study than in the reference studies. 39.4% received an ACE-inhibitor, 41.6% statins and 41.4% aspirin. Conclusion: Taking into consideration the results of recent large clinical trials indicating that very strict treatment goals are of no additional benefit, most patients in Swiss primary care would not benefit from a treatment intensification regarding HbA1c, blood pressure and cholesterol targets. Evidence-performance-gaps were observed mainly concerning the choice of first line medication.
在日常实践中,指南和2型糖尿病(T2DM)治疗之间的证据表现差距已被报道,特别是在初级保健中。我们的目的是评估当前初级保健治疗与指南以及指南所基于的大型临床试验(即UKPDS、accord、ADVANCE、STENO-2和VADT)患者特征之间的潜在差距。方法:我们进行了一项横断面研究,并从瑞士GP网络的临床信息系统中提取了541例T2DM患者的数据。结果:我们的研究人群与基线时ACCORD、ADVANCE和VADT的患者相当。UKPDS和STENO-2患者在年龄和病程上存在差异。本研究中hba1c水平(7.3%)、ldl水平(2.6 mmol/l)、收缩压和舒张压(135/78 mmHg)均低于参考研究。39.4%的患者服用了ace抑制剂,41.6%的患者服用了他汀类药物,41.4%的患者服用了阿司匹林。结论:考虑到最近的大型临床试验结果表明,非常严格的治疗目标没有额外的益处,瑞士初级保健的大多数患者不会从强化HbA1c、血压和胆固醇目标的治疗中获益。观察到的证据-性能差距主要涉及一线药物的选择。
{"title":"Evidence-performance gap in primary care revisited in patients with diabetes","authors":"S. Djalali, F. Mikulicic, K. Woitzek, C. Chmiel, O. Senn, T. Rosemann, M. Vecellio","doi":"10.5167/UZH-95058","DOIUrl":"https://doi.org/10.5167/UZH-95058","url":null,"abstract":"Evidence-performance-gaps between guidelines and treatment of type 2 diabetes (T2DM) in daily practice have been reported, especially in primary care. We aimed to assess the potential gap comparing current treatment in primary care with guidelines and patients’ characteristics from large clinical trials that guidelines are based on, namely UKPDS, ACCCORD, ADVANCE, STENO-2 and VADT. Methods: We undertook a cross-sectional study and extracted data on 541 patients with T2DM from a clinical information system of a GP network in Switzerland. Results: Our study population was comparable to patients in ACCORD, ADVANCE and VADT at baseline. Patients in UKPDS and STENO-2 differed in age and disease duration. HbA1c-levels (7.3%), LDL-level (2.6 mmol/l), systolic and diastolic (135/78 mmHg) blood pressure were lower in our study than in the reference studies. 39.4% received an ACE-inhibitor, 41.6% statins and 41.4% aspirin. Conclusion: Taking into consideration the results of recent large clinical trials indicating that very strict treatment goals are of no additional benefit, most patients in Swiss primary care would not benefit from a treatment intensification regarding HbA1c, blood pressure and cholesterol targets. Evidence-performance-gaps were observed mainly concerning the choice of first line medication.","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"9 7 1","pages":"1655-1664"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87718839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Correlation between major adverse cardiac events and coronary plaque characteristics. 主要心脏不良事件与冠状动脉斑块特征的相关性。
Pub Date : 2013-01-01
Bin He, Luyue Gai, Jingjing Gai, Huaiyu Qiao, Shuoyang Zhang, Zhiwei Guan, Li Yang, Yundai Chen

Background: Unstable plaque is believed to be responsible for major adverse cardiac events (MACE).

Objective: To determine whether coronary computed tomography angiography (CCTA) could be used to predict future MACE.

Methods: Patients undergoing CCTA between January 2008 and February 2010 were consecutively enrolled in the study. The hospital database was screened for patients who later developed acute ST segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) or cardiac death. Plaque scores were calculated and analyzed using one-way ANOVA to examine the relationship between plaque scores and MACE.

Results: Of the 8557 patients who underwent CCTA, 1055 had hospital records available for follow-up. During follow-up, 25 patients experienced MACE including death (six patients), heart failure (two patients), STEMI (11 patients) and NSTEMI (six patients). The plaque scores were significantly increased in patients who later died, developed heart failure or experienced STEMI (P<0.05). Calcification, erosion and severe stenosis were responsible for the events (P<0.05). Mild and moderate lesions, positive remodelling, drug-eluting stent placement, occlusion and diffuse lesions were not predictive of MACE (P>0.05).

Conclusion: Severe calcification, erosion and severe stenosis predict death, heart failure and STEMI.

背景:不稳定斑块被认为是主要心脏不良事件(MACE)的原因。目的:探讨冠状动脉ct血管造影(CCTA)是否可用于预测未来的MACE。方法:2008年1月至2010年2月期间接受CCTA治疗的患者连续入组。医院数据库筛选了后来发展为急性ST段抬高型心肌梗死(STEMI)、非STEMI (NSTEMI)或心源性死亡的患者。使用单因素方差分析计算和分析斑块评分,以检验斑块评分与MACE之间的关系。结果:在8557例接受CCTA的患者中,1055例有随访的医院记录。随访期间,25例患者发生MACE,包括死亡(6例)、心力衰竭(2例)、STEMI(11例)和NSTEMI(6例)。斑块评分在死亡、心力衰竭或STEMI患者中显著升高(P0.05)。结论:严重钙化、糜烂和严重狭窄可预测死亡、心力衰竭和STEMI。
{"title":"Correlation between major adverse cardiac events and coronary plaque characteristics.","authors":"Bin He,&nbsp;Luyue Gai,&nbsp;Jingjing Gai,&nbsp;Huaiyu Qiao,&nbsp;Shuoyang Zhang,&nbsp;Zhiwei Guan,&nbsp;Li Yang,&nbsp;Yundai Chen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Unstable plaque is believed to be responsible for major adverse cardiac events (MACE).</p><p><strong>Objective: </strong>To determine whether coronary computed tomography angiography (CCTA) could be used to predict future MACE.</p><p><strong>Methods: </strong>Patients undergoing CCTA between January 2008 and February 2010 were consecutively enrolled in the study. The hospital database was screened for patients who later developed acute ST segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) or cardiac death. Plaque scores were calculated and analyzed using one-way ANOVA to examine the relationship between plaque scores and MACE.</p><p><strong>Results: </strong>Of the 8557 patients who underwent CCTA, 1055 had hospital records available for follow-up. During follow-up, 25 patients experienced MACE including death (six patients), heart failure (two patients), STEMI (11 patients) and NSTEMI (six patients). The plaque scores were significantly increased in patients who later died, developed heart failure or experienced STEMI (P<0.05). Calcification, erosion and severe stenosis were responsible for the events (P<0.05). Mild and moderate lesions, positive remodelling, drug-eluting stent placement, occlusion and diffuse lesions were not predictive of MACE (P>0.05).</p><p><strong>Conclusion: </strong>Severe calcification, erosion and severe stenosis predict death, heart failure and STEMI.</p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 2","pages":"e71-6"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718602/pdf/ecc18e071.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31652912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. 肺栓塞,第一部分:流行病学,危险因素和危险分层,病理生理学,临床表现,诊断和非血栓性肺栓塞。
Pub Date : 2013-01-01
Jan Bĕlohlávek, Vladimír Dytrych, Aleš Linhart

Pulmonary embolism is an important clinical entity with considerable mortality despite advances in diagnosis and treatment. In the present article, the authors offer a comprehensive review focused mainly on epidemiology, risk factors, risk stratification, pathophysiological considerations and clinical presentation. Diagnosis based on assessment of clinical likelihood, electrocardiography, chest x-ray, D-dimer levels, markers of myocardial injury and overload, and blood gases is discussed in detail. Special attention is devoted to the clinical use of computed tomography, pulmonary angiography and echocardiography in the setting of pulmonary embolism.

尽管在诊断和治疗方面取得了进展,但肺栓塞是一种重要的临床疾病,死亡率很高。在这篇文章中,作者提供了一个全面的综述,主要集中在流行病学,危险因素,危险分层,病理生理考虑和临床表现。基于临床可能性评估、心电图、胸部x线、d -二聚体水平、心肌损伤和过载标志物以及血气的诊断进行了详细讨论。特别关注计算机断层扫描,肺血管造影和超声心动图在肺栓塞的临床应用。
{"title":"Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism.","authors":"Jan Bĕlohlávek,&nbsp;Vladimír Dytrych,&nbsp;Aleš Linhart","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pulmonary embolism is an important clinical entity with considerable mortality despite advances in diagnosis and treatment. In the present article, the authors offer a comprehensive review focused mainly on epidemiology, risk factors, risk stratification, pathophysiological considerations and clinical presentation. Diagnosis based on assessment of clinical likelihood, electrocardiography, chest x-ray, D-dimer levels, markers of myocardial injury and overload, and blood gases is discussed in detail. Special attention is devoted to the clinical use of computed tomography, pulmonary angiography and echocardiography in the setting of pulmonary embolism. </p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 2","pages":"129-38"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718593/pdf/ecc18129.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31652971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies. 慢性腹泻作为轻链淀粉样变的最初临床表现,并累及心脏,尽管十二指肠和直肠活检呈阴性。
Pub Date : 2013-01-01
Christian Pfluecke, Stefan Ulbrich, Karim Ibrahim, Kathrin D Geiger, Ruth H Strasser, Carsten Wunderlich

Early and accurate diagnosis and a prompt initiation of treatment are critical for the prognosis of light-chain amyloidosis. The present article describes a case involving a 62-year-old patient who experienced unexplained, chronic diarrhea with negative duodenal and rectal biopsies. Serum immunofixation, a free light-chain assay, electrocardiography and echocardiography were performed after the patient developed syncope. The results of these diagnostic investigations showed characteristic signs of systemic amyloidosis. Cardiac and bone marrow biopsies confirmed the diagnosis of systemic light-chain amyloidosis. The chronic diarrhea was found to be due to an autonomic neuropathy of the enteric nervous system.

早期准确诊断和及时开始治疗对轻链淀粉样变的预后至关重要。这篇文章描述了一个涉及62岁患者的病例,他经历了不明原因的慢性腹泻,十二指肠和直肠活检阴性。患者发生晕厥后进行血清免疫固定、游离轻链试验、心电图和超声心动图检查。这些诊断调查的结果显示系统性淀粉样变性的特征性征象。心脏和骨髓活检证实系统性轻链淀粉样变的诊断。慢性腹泻被发现是由于肠道神经系统的自主神经病变。
{"title":"Chronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies.","authors":"Christian Pfluecke,&nbsp;Stefan Ulbrich,&nbsp;Karim Ibrahim,&nbsp;Kathrin D Geiger,&nbsp;Ruth H Strasser,&nbsp;Carsten Wunderlich","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Early and accurate diagnosis and a prompt initiation of treatment are critical for the prognosis of light-chain amyloidosis. The present article describes a case involving a 62-year-old patient who experienced unexplained, chronic diarrhea with negative duodenal and rectal biopsies. Serum immunofixation, a free light-chain assay, electrocardiography and echocardiography were performed after the patient developed syncope. The results of these diagnostic investigations showed characteristic signs of systemic amyloidosis. Cardiac and bone marrow biopsies confirmed the diagnosis of systemic light-chain amyloidosis. The chronic diarrhea was found to be due to an autonomic neuropathy of the enteric nervous system. </p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 2","pages":"148-50"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718595/pdf/ecc18148.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31652973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ischemic postconditioning decreases matrix metalloproteinase-2 expression during ischemia-reperfusion of myocardium in a rabbit model: A preliminary report. 缺血后适应降低兔心肌缺血再灌注过程中基质金属蛋白酶-2的表达:初步报告。
Pub Date : 2013-01-01
Zhong-Zhi Liu, Jing-Bo Kong, Feng-Zhi Li, Long-Le Ma, Shu-Qin Liu, Le-Xin Wang

Objective: To investigate the effect of ischemic postconditioning on the expression of matrix metalloproteinase (MMP)-2 during ischemia-reperfusion of myocardium in a rabbit model.

Methods: Thirty-six male New Zealand white rabbits were randomly divided into sham, ischemia-reperfusion and ischemic postconditioning groups. Myocardial ischemia-reperfusion was created by ligating the left anterior descending coronary artery for 30 min followed by 3 h of reperfusion. Myocardial infarction sizes were determined by dual staining with triphenyltetrazolium chloride and trypan blue. Plasma levels of MMP-2 were measured using ELISA. Myocardial MMP-2 messenger RNA was analyzed by reverse transcription polymerase chain reaction.

Results: The mean (± SD) infarct size in the ischemic postconditioning group was significantly smaller compared with the ischemia-reperfusion group (37.1±3.8% versus 57.5±1.9%; P=0.02). The incidence of ventricular tachycardia in the ischemic postconditioning group was also lower than in the ischemia-reperfusion group (8.5% versus 75%; P=0.003). MMP-2 messenger RNA expression in the ischemic postconditioning group was significantly lower compared with the ischemia-reperfusion group (0.4944±0.0476 versus 0.6989±0.0694; P=0.02).

Conclusion: Ischemic postconditioning reduces myocardial ischemia-reperfusion injury, possibly by inhibiting the expression of MMP-2.

目的:探讨缺血后处理对兔心肌缺血再灌注过程中基质金属蛋白酶(MMP)-2表达的影响。方法:36只雄性新西兰大白兔随机分为假手术组、缺血再灌注组和缺血后适应组。结扎左冠状动脉前降支30min,再灌注3h,形成心肌缺血再灌注。心肌梗死大小采用三苯基四唑氯和台盼蓝双染色法测定。ELISA法检测血浆MMP-2水平。逆转录聚合酶链反应分析心肌MMP-2信使RNA。结果:缺血后适应组的平均梗死面积(±SD)明显小于缺血再灌注组(37.1±3.8% vs 57.5±1.9%;P = 0.02)。缺血后适应组室性心动过速的发生率也低于缺血再灌注组(8.5%对75%;P = 0.003)。缺血后适应组MMP-2信使RNA表达明显低于缺血再灌注组(0.4944±0.0476 vs 0.6989±0.0694;P = 0.02)。结论:缺血后处理可能通过抑制MMP-2的表达而减轻心肌缺血再灌注损伤。
{"title":"Ischemic postconditioning decreases matrix metalloproteinase-2 expression during ischemia-reperfusion of myocardium in a rabbit model: A preliminary report.","authors":"Zhong-Zhi Liu,&nbsp;Jing-Bo Kong,&nbsp;Feng-Zhi Li,&nbsp;Long-Le Ma,&nbsp;Shu-Qin Liu,&nbsp;Le-Xin Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of ischemic postconditioning on the expression of matrix metalloproteinase (MMP)-2 during ischemia-reperfusion of myocardium in a rabbit model.</p><p><strong>Methods: </strong>Thirty-six male New Zealand white rabbits were randomly divided into sham, ischemia-reperfusion and ischemic postconditioning groups. Myocardial ischemia-reperfusion was created by ligating the left anterior descending coronary artery for 30 min followed by 3 h of reperfusion. Myocardial infarction sizes were determined by dual staining with triphenyltetrazolium chloride and trypan blue. Plasma levels of MMP-2 were measured using ELISA. Myocardial MMP-2 messenger RNA was analyzed by reverse transcription polymerase chain reaction.</p><p><strong>Results: </strong>The mean (± SD) infarct size in the ischemic postconditioning group was significantly smaller compared with the ischemia-reperfusion group (37.1±3.8% versus 57.5±1.9%; P=0.02). The incidence of ventricular tachycardia in the ischemic postconditioning group was also lower than in the ischemia-reperfusion group (8.5% versus 75%; P=0.003). MMP-2 messenger RNA expression in the ischemic postconditioning group was significantly lower compared with the ischemia-reperfusion group (0.4944±0.0476 versus 0.6989±0.0694; P=0.02).</p><p><strong>Conclusion: </strong>Ischemic postconditioning reduces myocardial ischemia-reperfusion injury, possibly by inhibiting the expression of MMP-2.</p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 2","pages":"e99-e101"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718608/pdf/ecc18e099.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31652837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxidative stress: Predictive marker for coronary artery disease. 氧化应激:冠状动脉疾病的预测指标。
Pub Date : 2013-01-01
Teodora Vichova, Zuzana Motovska

The role of oxidative stress in cardiovascular disease processes, such as atherogenesis, ischemic-reperfusion injury and cardiac remodelling, has been increasingly recognized in the past few decades. Currently, an increasing number of studies suggest that levels of oxidative stress markers in body fluids correlate with atherosclerotic disease activity. This finding may lead to novel clinical approaches in patients with coronary artery disease. Assessment of oxidative stress markers could modify risk stratification and treatment of patients with suspected coronary artery disease or myocardial infarction.

氧化应激在心血管疾病过程中的作用,如动脉粥样硬化、缺血-再灌注损伤和心脏重构,在过去的几十年里已经越来越被认识到。目前,越来越多的研究表明,体液中氧化应激标志物的水平与动脉粥样硬化疾病活动相关。这一发现可能为冠状动脉疾病患者提供新的临床方法。氧化应激标志物的评估可以改变疑似冠状动脉疾病或心肌梗死患者的风险分层和治疗。
{"title":"Oxidative stress: Predictive marker for coronary artery disease.","authors":"Teodora Vichova,&nbsp;Zuzana Motovska","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The role of oxidative stress in cardiovascular disease processes, such as atherogenesis, ischemic-reperfusion injury and cardiac remodelling, has been increasingly recognized in the past few decades. Currently, an increasing number of studies suggest that levels of oxidative stress markers in body fluids correlate with atherosclerotic disease activity. This finding may lead to novel clinical approaches in patients with coronary artery disease. Assessment of oxidative stress markers could modify risk stratification and treatment of patients with suspected coronary artery disease or myocardial infarction. </p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 2","pages":"e88-91"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718605/pdf/ecc18e088.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31652915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Right ventricular myocardial infarction: From pathophysiology to prognosis. 右心室心肌梗死:从病理生理到预后。
Pub Date : 2013-01-01
Tomas Ondrus, Jan Kanovsky, Tomas Novotny, Irena Andrsova, Jindrich Spinar, Petr Kala

Right ventricle myocardial infarctions (RVMIs) accompany inferior wall ischemia in up to one-half of cases. The clinical sequelae of RVMIs vary from no hemodynamic compromise to severe hypotension and cardiogenic shock. Diagnosis is based on physical examination, electrocardiography, echocardiography and coronary angiography. Because the standard 12-lead electrocardiogram is insufficient for the assessment of RV involvement, right-sided precordial leads should always be included. Adequate fluid administration in combination with positive inotropic agents and early coronary reperfusion are crucial components of treatment, while diuretics and nitrates should be avoided. Intra-aortic balloon counterpulsation and right ventricle assist devices may be used with success in RVMIs associated with medically refractory heart failure. Right ventricular involvement appears to be an independent prognostic factor that dramatically increases in-hospital mortality, due, in part, to a significantly higher risk of hemodynamically compromising arrhythmias. Thus, using right-sided precordial leads and early RVMI identification to trigger an appropriately aggressive treatment protocol may improve patients' prognosis.

右心室心肌梗死(RVMIs)伴随下壁缺血在多达一半的病例。RVMIs的临床后遗症从无血流动力学损害到严重低血压和心源性休克不等。诊断依据是体格检查、心电图、超声心动图和冠状动脉造影。由于标准的12导联心电图不足以评估右心室受累情况,因此应始终包括右侧心前导联。适当的液体管理联合正性肌力药物和早期冠状动脉再灌注是治疗的关键组成部分,而利尿剂和硝酸盐应避免使用。主动脉内球囊反搏和右心室辅助装置可成功用于与医学难治性心力衰竭相关的RVMIs。右室受累似乎是一个独立的预后因素,它显著增加了住院死亡率,部分原因是血液动力学损害心律失常的风险显著增加。因此,使用右侧心前导联和早期RVMI识别来触发适当的积极治疗方案可能会改善患者的预后。
{"title":"Right ventricular myocardial infarction: From pathophysiology to prognosis.","authors":"Tomas Ondrus,&nbsp;Jan Kanovsky,&nbsp;Tomas Novotny,&nbsp;Irena Andrsova,&nbsp;Jindrich Spinar,&nbsp;Petr Kala","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Right ventricle myocardial infarctions (RVMIs) accompany inferior wall ischemia in up to one-half of cases. The clinical sequelae of RVMIs vary from no hemodynamic compromise to severe hypotension and cardiogenic shock. Diagnosis is based on physical examination, electrocardiography, echocardiography and coronary angiography. Because the standard 12-lead electrocardiogram is insufficient for the assessment of RV involvement, right-sided precordial leads should always be included. Adequate fluid administration in combination with positive inotropic agents and early coronary reperfusion are crucial components of treatment, while diuretics and nitrates should be avoided. Intra-aortic balloon counterpulsation and right ventricle assist devices may be used with success in RVMIs associated with medically refractory heart failure. Right ventricular involvement appears to be an independent prognostic factor that dramatically increases in-hospital mortality, due, in part, to a significantly higher risk of hemodynamically compromising arrhythmias. Thus, using right-sided precordial leads and early RVMI identification to trigger an appropriately aggressive treatment protocol may improve patients' prognosis. </p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 1","pages":"27-30"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716484/pdf/ecc18027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31916431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent ductus arteriosus closure using an Amplatzer(™) ventricular septal defect closure device. 使用Amplatzer(™)室间隔缺损关闭装置关闭动脉导管未闭。
Pub Date : 2013-01-01
Rajeev Fernando, Ketan Koranne, Pranav Loyalka, Biswajit Kar, Igor Gregoric

The ductus arteriosus originates from the persistence of the distal portion of the left sixth aortic arch. It connects the descending aorta (immediately distal to the left subclavian artery) to the roof of the main pulmonary artery, near the origin of the left pulmonary artery. Persistence of the duct beyond 48 h after birth is abnormal and results in patent ductus arteriosus (PDA). PDA is rare in adults because it is usually discovered and treated in childhood. Mechanical closure remains the definitive therapy because the patency of ductus arteriosus may lead to multiple complications, depending on the size and flow through the ductus. PDA closure is indicated in patients with symptoms and evidence of left heart enlargement, and in patients with elevated pulmonary pressures when reversal is possible. Transcatheter closure is the preferred technique in adults because it avoids sternotomy, reduces the length of hospital stay and is associated with fewer complications compared with surgery. First demonstrated in 1967, both the technique and the occluder devices used have since evolved. However, designing an ideal PDA occluder has been a challenge due to the variability in size, shape and orientation of PDAs. The present article describes a case involving a 35-year-old woman who presented to the Center for Advanced Heart Failure (Houston, USA) with congestive heart failure due to a large PDA, which was successfully occluded using an Amplatzer (St Jude Medical, USA) muscular ventricular septal defect closure device. The wider waist and dual-retention discs of these ventricular septal defect closure devices may be important factors to consider in the future development of devices for the occlusion of large PDAs.

动脉导管起源于左侧第六主动脉弓远端部分。它连接降主动脉(紧靠左锁骨下动脉远端)和肺动脉主动脉顶部,靠近左肺动脉的起点。出生后导管持续超过48小时是不正常的,导致动脉导管未闭(PDA)。PDA在成人中是罕见的,因为它通常在儿童时期被发现和治疗。机械闭合仍然是最终的治疗方法,因为动脉导管通畅可能导致多种并发症,这取决于动脉导管的大小和流量。对于有左心增大症状和证据的患者,以及有可能逆转的肺动脉压升高的患者,应关闭PDA。经导管闭合术是成人的首选技术,因为它避免了胸骨切开术,缩短了住院时间,与手术相比并发症更少。首次演示于1967年,技术和使用的咬合装置都已发展。然而,由于PDA的尺寸、形状和方向的可变性,设计理想的PDA封堵器一直是一个挑战。这篇文章描述了一个35岁的女性,她到晚期心力衰竭中心(休斯顿,美国),由于一个大的PDA导致充血性心力衰竭,使用Amplatzer (St Jude Medical,美国)肌肉室间隔缺损关闭装置成功闭塞。这些室间隔缺损封闭装置的宽腰和双保留盘可能是未来开发大型pda闭塞装置时需要考虑的重要因素。
{"title":"Patent ductus arteriosus closure using an Amplatzer(™) ventricular septal defect closure device.","authors":"Rajeev Fernando,&nbsp;Ketan Koranne,&nbsp;Pranav Loyalka,&nbsp;Biswajit Kar,&nbsp;Igor Gregoric","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The ductus arteriosus originates from the persistence of the distal portion of the left sixth aortic arch. It connects the descending aorta (immediately distal to the left subclavian artery) to the roof of the main pulmonary artery, near the origin of the left pulmonary artery. Persistence of the duct beyond 48 h after birth is abnormal and results in patent ductus arteriosus (PDA). PDA is rare in adults because it is usually discovered and treated in childhood. Mechanical closure remains the definitive therapy because the patency of ductus arteriosus may lead to multiple complications, depending on the size and flow through the ductus. PDA closure is indicated in patients with symptoms and evidence of left heart enlargement, and in patients with elevated pulmonary pressures when reversal is possible. Transcatheter closure is the preferred technique in adults because it avoids sternotomy, reduces the length of hospital stay and is associated with fewer complications compared with surgery. First demonstrated in 1967, both the technique and the occluder devices used have since evolved. However, designing an ideal PDA occluder has been a challenge due to the variability in size, shape and orientation of PDAs. The present article describes a case involving a 35-year-old woman who presented to the Center for Advanced Heart Failure (Houston, USA) with congestive heart failure due to a large PDA, which was successfully occluded using an Amplatzer (St Jude Medical, USA) muscular ventricular septal defect closure device. The wider waist and dual-retention discs of these ventricular septal defect closure devices may be important factors to consider in the future development of devices for the occlusion of large PDAs. </p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 1","pages":"e50-4"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716504/pdf/ecc18e050.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31917914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cocaine-induced coronary stent thrombosis. 可卡因引起的冠状动脉支架血栓。
Pub Date : 2013-01-01
Morhaf Ibrahim, Reham Hasan, Mustafa Awan

Cocaine is the most commonly abused drug in patients presenting to emergency rooms. Compliance with medical instructions and medications is poor in patients who use cocaine. A case involving a 41-year-old cocaine user who developed subacute stent thrombosis is described. The patient underwent bare metal stent implantation three days before presentation and had confirmed compliance with dual antiplatelet therapy. The stent thrombosis was treated with a manual and mechanical thrombectomy, in addition to percutaneous transluminal coronary angioplasty. Given the issue of compliance and the increased evidence of cocaine-induced thrombosis in native vessels and stents, it is recommended that balloon angioplasty alone should be the treatment of choice when intervention is required.

在急诊室就诊的病人中,可卡因是最常见的滥用药物。使用可卡因的患者对医疗指示和药物的依从性很差。一个病例涉及41岁可卡因使用者谁发展亚急性支架血栓被描述。患者在就诊前三天接受了裸金属支架植入术,并证实了双重抗血小板治疗的依从性。支架内血栓形成除经皮腔内冠状动脉成形术外,还采用手动和机械取栓术治疗。考虑到依从性问题以及可卡因引起的血管和支架血栓形成的证据增加,建议当需要干预时,单独的球囊血管成形术应该是治疗的选择。
{"title":"Cocaine-induced coronary stent thrombosis.","authors":"Morhaf Ibrahim,&nbsp;Reham Hasan,&nbsp;Mustafa Awan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cocaine is the most commonly abused drug in patients presenting to emergency rooms. Compliance with medical instructions and medications is poor in patients who use cocaine. A case involving a 41-year-old cocaine user who developed subacute stent thrombosis is described. The patient underwent bare metal stent implantation three days before presentation and had confirmed compliance with dual antiplatelet therapy. The stent thrombosis was treated with a manual and mechanical thrombectomy, in addition to percutaneous transluminal coronary angioplasty. Given the issue of compliance and the increased evidence of cocaine-induced thrombosis in native vessels and stents, it is recommended that balloon angioplasty alone should be the treatment of choice when intervention is required. </p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 1","pages":"e57-9"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716507/pdf/ecc18e057.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31917916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats. 小剂量羟氯喹对大鼠梗死周围心肌磷酸化Akt和p53蛋白表达及心肌细胞凋亡的影响。
Pub Date : 2013-01-01
Jing Zhou, Gang Li, Zhi-Hua Wang, Li-Ping Wang, Pu-Jiang Dong

Background: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.

Objective: To explore the effects of low-dose HCQ on the expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium in a rat model.

Methods: Myocardial infarction (MI) was induced experimentally in a subset of rats, while others underwent sham operation (sham). Three days after operation, surviving Sprague-Dawley male rats were divided into MI+HCQ, MI, sham+HCQ and sham groups. MI+HCQ and sham + HCQ groups were treated with HCQ (3.4 mg/kg); and MI and sham groups were treated with phosphate buffered (ie, physiological) saline (10 mL/kg) by gavage every day for 12 weeks. The expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium was detected by Western blot and terminal deoxynucleotidyl transferase dUTP nick end labelling, respectively.

Results: Twelve weeks after treatment, the expression of phosphorylated Akt protein was significantly increased (P<0.05). Expression of phosphorylated p53 protein was not significantly different (P>0.05) in the peri-infarct myocardium of the MI+HCQ group from that in the MI group. The cardiomyocyte apoptosis rate in the peri-infarct myocardium was significantly decreased in the MI+HCQ group compared with the MI group (P<0.05).

Conclusion: Low-dose HCQ can significantly increase the expression of phosphorylated Akt protein without significantly impacting expression of phosphorylated p53 protein in the peri-infarct myocardium. Accordingly, it can inhibit cardiomyocyte apoptosis in the peri-infarct myocardium.

背景:低剂量羟氯喹(HCQ)和共济失调毛细血管扩张突变(ATM)蛋白激酶最近被认为有助于预防年龄相关的代谢综合征,包括高血压、高胆固醇血症和葡萄糖耐受不良;然而,低剂量HCQ对梗死周围心肌ATM下游磷酸化Akt(蛋白激酶B)和p53蛋白表达及心肌细胞凋亡的影响尚不清楚。目的:探讨低剂量HCQ对大鼠梗死周围心肌组织磷酸化Akt、p53蛋白表达及心肌细胞凋亡的影响。方法:用实验方法诱导一部分大鼠心肌梗死(MI),另一部分进行假手术(sham)。术后3 d,将存活雄性sd大鼠分为心肌梗死+HCQ组、心肌梗死组、假手术组和假手术组。MI+HCQ组和sham +HCQ组给予HCQ (3.4 mg/kg)治疗;心肌梗死组和假手术组每天灌胃磷酸缓冲生理盐水(10 mL/kg),连续12周。Western blot和末端脱氧核苷酸转移酶dUTP缺口末端标记分别检测梗死周围心肌中磷酸化Akt和p53蛋白的表达和心肌细胞凋亡情况。结果:治疗12周后,心肌梗死+HCQ组梗死周心肌组织中磷酸化Akt蛋白的表达较心肌梗死组显著升高(P0.05)。与MI组相比,MI+HCQ组梗死周围心肌细胞凋亡率显著降低(p)。结论:低剂量HCQ可显著增加梗死周围心肌磷酸化Akt蛋白的表达,但不显著影响磷酸化p53蛋白的表达。因此,它可以抑制梗死周围心肌细胞的凋亡。
{"title":"Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats.","authors":"Jing Zhou,&nbsp;Gang Li,&nbsp;Zhi-Hua Wang,&nbsp;Li-Ping Wang,&nbsp;Pu-Jiang Dong","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.</p><p><strong>Objective: </strong>To explore the effects of low-dose HCQ on the expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium in a rat model.</p><p><strong>Methods: </strong>Myocardial infarction (MI) was induced experimentally in a subset of rats, while others underwent sham operation (sham). Three days after operation, surviving Sprague-Dawley male rats were divided into MI+HCQ, MI, sham+HCQ and sham groups. MI+HCQ and sham + HCQ groups were treated with HCQ (3.4 mg/kg); and MI and sham groups were treated with phosphate buffered (ie, physiological) saline (10 mL/kg) by gavage every day for 12 weeks. The expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium was detected by Western blot and terminal deoxynucleotidyl transferase dUTP nick end labelling, respectively.</p><p><strong>Results: </strong>Twelve weeks after treatment, the expression of phosphorylated Akt protein was significantly increased (P<0.05). Expression of phosphorylated p53 protein was not significantly different (P>0.05) in the peri-infarct myocardium of the MI+HCQ group from that in the MI group. The cardiomyocyte apoptosis rate in the peri-infarct myocardium was significantly decreased in the MI+HCQ group compared with the MI group (P<0.05).</p><p><strong>Conclusion: </strong>Low-dose HCQ can significantly increase the expression of phosphorylated Akt protein without significantly impacting expression of phosphorylated p53 protein in the peri-infarct myocardium. Accordingly, it can inhibit cardiomyocyte apoptosis in the peri-infarct myocardium.</p>","PeriodicalId":54377,"journal":{"name":"Experimental & Clinical Cardiology","volume":"18 2","pages":"e95-8"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718607/pdf/ecc18e095.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31652917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental & Clinical Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1